Patent application

REPEAT - Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent

Retrieved on: 
Monday, June 14, 2021

Over the last four months Vocan has made great strides in further developing its biosynthetic psilocybin production method and has started collecting data to substantiate our drafted provisional patent.

Key Points: 
  • Over the last four months Vocan has made great strides in further developing its biosynthetic psilocybin production method and has started collecting data to substantiate our drafted provisional patent.
  • As such, we anticipate a forthcoming filing of our provisional patent application.
  • Vocans provisional patent application for the biosynthetic processing of psilocybin addresses the many inefficiencies and cost prohibitions of current psilocybin production methods.
  • Core One Labs submitting its patent for its revolutionary biosynthetic psilocybin production system is imminent as we are justdays away.

Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent

Retrieved on: 
Saturday, June 12, 2021

Over the last four months Vocan has made great strides in further developing its biosynthetic psilocybin production method and has started collecting data to substantiate our drafted provisional patent.

Key Points: 
  • Over the last four months Vocan has made great strides in further developing its biosynthetic psilocybin production method and has started collecting data to substantiate our drafted provisional patent.
  • As such, we anticipate a forthcoming filing of our provisional patent application.
  • Vocans provisional patent application for the biosynthetic processing of psilocybin addresses the many inefficiencies and cost prohibitions of current psilocybin production methods.
  • Core One Labs submitting its patent for its revolutionary biosynthetic psilocybin production system is imminent as we are justdays away.

Grant Thornton awarded patent for innovative technology in cta.x — an app for rapid, automated controls testing

Retrieved on: 
Thursday, June 10, 2021

Grant Thornton LLP has been awarded a patent by the U.S. Patent and Trademark Office for innovations related to the firms controls-test automation app, cta.x.

Key Points: 
  • Grant Thornton LLP has been awarded a patent by the U.S. Patent and Trademark Office for innovations related to the firms controls-test automation app, cta.x.
  • The cta.x app automates and integrates controls testing by taking existing assurance processes and applying them to the full population of procedures and policies governing controls.
  • Beyond the current patent, Grant Thornton has patent applications pending for additional innovations related to the cta.x app and the firms other new technologies.
  • Grant Thornton refers to Grant Thornton LLP, the U.S. member firm of Grant Thornton International Ltd (GTIL).

NxGen Brands, Signs Letter of Intent (LOI) to Acquire HealthCard, Technology Company That Has Patent Pending Registration for Patient Centric Universal Health Recording & Payment Card

Retrieved on: 
Tuesday, June 8, 2021

HealthCard, LLC ("HealthCard") filed U.S. patent application number 15/944867 with the patent office on 2019-10-10 for"System and Method for Patient-Centric Universal Health Recording and Payment".

Key Points: 
  • HealthCard, LLC ("HealthCard") filed U.S. patent application number 15/944867 with the patent office on 2019-10-10 for"System and Method for Patient-Centric Universal Health Recording and Payment".
  • Technologies can be implemented for both private providers and governmental standardization of health record management.
  • He continued: "Our target business models/uses are:
    Digitalizing medical records for emerging markets while standardizing existing document recording.
  • NxGen Brands Inc. is a multifaceted public company comprised of essential business industries that serve various market segments.

MeaTech Announces Filing of Provisional Patent Application for Novel Bioprinting Method

Retrieved on: 
Thursday, June 3, 2021

The patent application is directed to a novel method for bioprinting that MeaTech believes has the potential to provide exceptional control of bioink printing during multi-layered bioprinting process.

Key Points: 
  • The patent application is directed to a novel method for bioprinting that MeaTech believes has the potential to provide exceptional control of bioink printing during multi-layered bioprinting process.
  • MeaTech believes these attributes could allow for bioprinting resolutions that are highly advantageous in achieving premium, thick meat emulating products.
  • The filing of this provisional patent application directly relates to MeaTech's cellular agriculture 3D bioprinting goals to produce premium cuts of (animal) cell-based cuts of meat.
  • To date, MeaTech has a portfolio of six provisional and non-provisional patent applications with the USPTO and World Intellectual Property Organization (WIPO) filed through the PCT.

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

Retrieved on: 
Wednesday, June 2, 2021

This European patent was filed as a divisional application and follows the grant of the European parent patent announced in November 2018, and the corresponding United States patents announced in December 2020 and March 2021.

Key Points: 
  • This European patent was filed as a divisional application and follows the grant of the European parent patent announced in November 2018, and the corresponding United States patents announced in December 2020 and March 2021.
  • The claims are also directed to related methods of use in the treatment of cancer.
  • It also highlights the critical investments we are making to protect efti which underpin further clinical development and commercialisation of this asset.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

RIVANNA's Accuro Product-Line Expansion Fortified With European Notice of Allowance

Retrieved on: 
Wednesday, June 2, 2021

CHARLOTTESVILLE, Va., June 2, 2021 /PRNewswire/ --RIVANNA, developers of world-first, imaging-based medical solutions, announced the European Patent Office has issued RIVANNA a notice of allowance for European patent application No.

Key Points: 
  • CHARLOTTESVILLE, Va., June 2, 2021 /PRNewswire/ --RIVANNA, developers of world-first, imaging-based medical solutions, announced the European Patent Office has issued RIVANNA a notice of allowance for European patent application No.
  • BoneVision provides precisely captured bony anatomical structures within a large field of view and demonstrated performance detecting small fractures with high sensitivity and specificity.
  • This allowance will help accelerate product-line expansion, building on patented technologies introduced with RIVANNA's flagship device, Accuro, which automates ultrasound image detection of spinal landmarks during spinal needle guidance procedures.
  • European Patent Office has issued RIVANNA a notice of allowance for European patent application.

Tauriga Sciences Inc. Prepares for Major Upcoming Product Launch and Introduces Expanded Tauri-Gummies™ Product Line

Retrieved on: 
Thursday, May 27, 2021

The Company is also planning a June 2021 launch of its expanded and enhanced Tauri-Gummies product line.This product launch will include: Original 25mg CBD infused gum drops (re-formulated without artificial colors), 25mg Delta 8 THC infused Blue Raspberry gummies, and 25mg Delta 8 THC + Melatonin + infused Wild Blueberry gummies.

Key Points: 
  • The Company is also planning a June 2021 launch of its expanded and enhanced Tauri-Gummies product line.This product launch will include: Original 25mg CBD infused gum drops (re-formulated without artificial colors), 25mg Delta 8 THC infused Blue Raspberry gummies, and 25mg Delta 8 THC + Melatonin + infused Wild Blueberry gummies.
  • Please visit our corporate website, for additional information, as well as inquiries, athttp://www.tauriga.com
    Complementary to the Companys retail business, is its ongoing Pharmaceutical Development initiative.
  • Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.The Patent, filed with the U.S.P.T.O.
  • Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances.

Enertopia Announces Filing of Second Provisional Patent Application

Retrieved on: 
Wednesday, May 26, 2021

Our Patent Attorneys have informed us our Second provisional patent application has been filed with the USPTO.

Key Points: 
  • Our Patent Attorneys have informed us our Second provisional patent application has been filed with the USPTO.
  • While our first provisional patent was geared towards the mining industry, our second provisional patent was created to safely extract heat from any PV panel for a multitude of uses.Key takeaways from the second provisional patent application are: it is a safe method to couple the absorber from our provisional patent #1 to the solar module, allowing for maximum heat transfer, which in turn allows for maximum PV production, an ideal thermal temperature, all while extending the life of the PV panels.
  • Provisional patent #2 is also a universal design, purposely created to interface and be used with and license to other pre-existing technologies.
  • Provisional patent #2 is also a universal design, purposely created to interface and be usedwith and license to other pre-existing technologies.

Poda Provides Update on its Patent Developments Over the Past Six Years

Retrieved on: 
Wednesday, May 26, 2021

VANCOUVER, BC, May 26, 2021 /PRNewswire/ - PODA LIFESTYLE AND WELLNESS LTD. ("Poda Lifestyle" or the "Company") (CSE: PODA) (FSE: 99L) is pleased to announce a comprehensive update on its patent developments that have been underway for the past six years.

Key Points: 
  • VANCOUVER, BC, May 26, 2021 /PRNewswire/ - PODA LIFESTYLE AND WELLNESS LTD. ("Poda Lifestyle" or the "Company") (CSE: PODA) (FSE: 99L) is pleased to announce a comprehensive update on its patent developments that have been underway for the past six years.
  • This patent provides PODA with protection based on the patent filings allowing PODA to be the only closed ended cigarette on the market.
  • In Summary PODA has filed numerous patents under PCT as follows:
    PCT WO 2018/165769 A1 Closed Bottom Vaporizer Pod Filed September 20, 2018.
  • Poda Lifestyle's HNB system is fully patented in Canada and is patent pending in 65 additional countries, covering over 70% of the global population.